{"id":"W4386697187","doi":"10.1016/j.clml.2023.09.003","title":"Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs; Regeneron Pharmaceuticals; Celgene; Array BioPharma; Alnylam Pharmaceuticals; National Comprehensive Cancer Network; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Lenalidomide; Daratumumab; Internal medicine; Multiple myeloma; Oncology; Progression-free survival; Population; Proportional hazards model; Confidence interval; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00474729,0.0002467593,0.0008401502,0.001409115,0.0004648527,0.0009915526,0.0007124698,0.000381782,0.002117645],"category_scores_gemma":[0.01042175,0.0002418249,0.001260184,0.002356029,0.0003163573,0.0006569721,0.0005164081,0.0003521362,0.0002611435],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002284575,"about_ca_system_score_gemma":0.002891177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007240718,"about_ca_topic_score_gemma":0.01488128,"domain_scores_codex":[0.9968191,0.001702349,0.0004256094,0.0004925146,0.0004452232,0.0001150217],"domain_scores_gemma":[0.9806199,0.004167352,0.01167209,0.0008091456,0.002003604,0.000727863],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08042698,0.001576995,0.7497725,0.01070457,0.008567419,0.0006639967,0.001416343,0.001589302,0.00187369,0.0009982846,0.01453106,0.1278789],"study_design_scores_gemma":[0.01957687,0.01641135,0.9251872,0.00310662,0.01038532,0.001001267,0.0008449594,0.002509129,0.001026598,0.0002417732,0.01959085,0.0001181456],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9609278,0.02620914,0.000470716,0.0004641479,0.00006413728,0.0009073397,0.008570117,0.00003288912,0.002353599],"genre_scores_gemma":[0.9884579,0.004807472,0.0008241709,0.0002417933,0.0001238565,0.000526267,0.004677079,0.00001053149,0.0003309562],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007240718,"threshold_uncertainty_score":0.02510637,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04650279661337501,"score_gpt":0.3550013715950573,"score_spread":0.3084985749816823,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}